SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CRINGE is a Solana meme token centered around all images, videos, and actions which are cringe!  Warning: Cringe Alert! Remember, folks! Just like we don't judge people based on race, ethnicity, or color, we shouldn't judge them for being cringe. After all, cringe isn't ugly - it's just... special. 😉  Embrace your inner cringe, because in a world full of copycats, being cringey is the new cool!  Meme coins are driven by community, and our community is CRINGE as heck!

CRINGE

CRINGE is gaining traction among retail traders as a low-cap speculative play, sparking intense community debate over its rapid growth potential versus the risks inherent in highly volatile crypto assets.

On November 2021, 4chan created a female alternative to Wojak/PePe called “GleGle.”

glegle

Investors are actively accumulating GLEGLE, viewing the current market structure as a deliberate setup rather than simple volatility. The community is focused on steady price action and early positioning, with many discussing potential long-term growth as they monitor the token's progress relative to other meme coin trends.

cowgorithm

COWGORITHM is gaining traction as investors speculate on potential synergies and community-driven migration from other related crypto assets. The conversation is largely fueled by grassroots enthusiasm and retail interest in building momentum around the token's ecosystem.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is seeing heightened community discussion surrounding the imminent Goliath mainnet launch and the role of its deflationary gas mechanism in institutional adoption. Traders remain polarized, with many debating the impact of upcoming infrastructure rollouts while others voice caution regarding historical price volatility and the project's long-term utility.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as investors and community members rally around its long-term focus on cannabis culture, decentralization, and ongoing development on the Solana blockchain. Discussions highlight a mix of enthusiasm for upcoming industry milestones and shared interest in the plant's medicinal and historical significance.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is currently trending as investors prepare for the fiscal year 2027 guidance and Q4 earnings report, with the community closely tracking the integration of QNX software into next-generation vehicle architectures like BMW's Neue Klasse. Sentiment is split between bullish long-term investors highlighting QNX's expanding footprint in robotics and ADAS, and skeptics expressing frustration over stagnant revenue growth and stock performance relative to broader market gains.

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

Alumis Inc.

Alumis Inc. is surging following positive Phase 3 results for envudeucitinib in plaque psoriasis, which demonstrated robust, deep skin clearance and a favorable safety profile across two global trials. The community is actively discussing the drug's competitive potential against existing oral therapies, with heightened interest in the upcoming NDA filing and potential buyout opportunities as the stock gathers significant momentum.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is generating significant market buzz as investors anticipate long-term clinical data presentations at the upcoming AAD Annual Meeting, which the community believes could cement sonelokimab's status as a best-in-class treatment for hidradenitis suppurativa. Active discussions center on potential buyout interest from major pharmaceutical firms and the stock's positioning as a de-risked late-stage asset, leading many to closely monitor institutional accumulation patterns despite recent price volatility.

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded on April 8, 1991 and is headquartered in Wilmington, DE.

Incyte Corp.

Incyte Corp. is trending as investors digest the company's recent strategic pivot, which includes pausing enrollment in a mid-stage clinical program due to preclinical toxicology findings. The community is actively debating the impact of this pipeline adjustment, with many scrutinizing management's allocation of capital and the company's long-term growth prospects beyond its flagship product, Jakafi.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Bristol-Myers Squibb is trending after successfully navigating a late-stage trial update for its Alzheimers-related psychosis program, which led to a strategic decision to expand enrollment rather than discontinue the study. Investors are currently weighing this pipeline resilience against broader sector volatility, with active community discussion focusing on the stock's valuation as a defensive value play and its long-term potential for a rebound driven by upcoming clinical readouts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sanofi Reports Positive Phase 3 Results For Amlitelimab In Atopic Dermatitis

(RTTNews) - Sanofi SA (SNY, SNYNF,SAN.PA) announced encouraging results from three Phase 3 clinical trialsCOAST 1, COAST 2, and SHOREevaluating amlitelimab, a fully human non-T cell depleting monoclonal antibody that selectively targets OX40-ligand (OX40L). The studies, present...

Dynamic Advisor Solutions LLC Decreases Stock Holdings in Sanofi $SNY

Dynamic Advisor Solutions LLC reduced its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 87.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,290 shares of the company's stock after selling 52,401 shares du...

Top Research Reports for Palantir, Linde and Arista Networks

Today's Research Daily features new research reports on 16 major stocks, including Palantir Technologies Inc. (PLTR), Linde plc (LIN) and Arista Networks, Inc. (ANET), as well as two micro-cap stocks, Comstock Holding Companies, Inc. (CHCI) and United Bancorp, Inc. (UBCP).

Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up

DNLI surges after FDA approves Avlayah, its first commercial drug and a breakthrough Hunter syndrome therapy targeting the brain.

REGN Soars 28.9% in Six Months: Is There More Upside Potential in 2026?

Regeneron's rally reflects biotech momentum as pipeline wins and Dupixent growth offset Eylea erosion amid intensifying competition.

<ul class="summary-bullets"><li>The bill proposes a pilot program in 10 states, allowing uninsured patients to access insulin at a capped price.</li><li>The bill also encourages lower list prices and increasing competition from generic and biosimilar options.</li><li>It aims to reform pharmacy benefit manager rebate systems, though funding details are not yet finalized.</li></ul>A bipartisan group of U.S. senators has reportedly reached a breakthrough deal to cap insulin prices at $35, aiming to ease the financial burden for millions living with diabetes.The proposal, led by Jeanne Shaheen and Susan Collins, now needs the backing of Senate Majority Leader John Thune and the approval of President Donald Trump, according to a Semafor <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.semafor.com/article/03/24/2026/senators-reach-deal-on-capping-insulin-costs-at-35">report</a> on Wednesday.<h2 class="st-heading-2">Bill Proposes Pilot Program In 10 States</h2>The plan initially focused on insured patients, while senators John Kennedy and Raphael Warnock pushed to include uninsured individuals. As a compromise, the bill proposes a pilot program in 10 states allowing uninsured patients to access insulin at a capped price.“I would really like to be able to leave the Senate thinking that we had helped to address insulin costs for a lot of Americans. This is the most expensive chronic disease,” Shaheen told Semafor.According to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cdc.gov/diabetes/php/data-research/index.html">report</a> by the Centers for Disease Control and Prevention in January, nearly 30 million Americans have been diagnosed with diabetes.&nbsp;&nbsp;The legislation also aims to cut costs by reforming pharmacy benefit manager rebate systems, though funding details are still being finalized.<h2 class="st-heading-2">Details Of The Proposal</h2>The bipartisan bill aims to lower insulin costs and expand access for patients. The bill would extend the $35 out-of-pocket cap, currently available to Medicare users, to those with private insurance.It also targets high insulin prices by encouraging lower list prices and increasing competition from generic and biosimilar options. In addition, the legislation ensures patients benefit directly from rebates and discounts typically handled by pharmacy benefit managers, helping reduce overall costs.Meanwhile, shares of top insulin producers traded mixed on Wednesday. Sanofi (SNY) stock was up 2%, while shares of Eli Lilly (LLY) gained 1.5%. Novo Nordisk (NVO) shares were down 1%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A woman holds an insulin pen with an exposed injection needle. Photo: Hannes P. Albert/dpa (Photo by Hannes P Albert/picture alliance via Getty Images)

Bipartisan US Senators Reportedly Reach Breakthrough To Cap Insulin Prices at $35 – SNY, LLY, NVO Stocks Gain Pre-Market

The proposal needs the backing of Senate Majority Leader John Thune and the approval of President Donald Trump, the report added.

Equity

DAVENPORT & Co LLC Sells 37,653 Shares of Sanofi $SNY

DAVENPORT & Co LLC lowered its position in Sanofi (NASDAQ:SNY - Free Report) by 1.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The...

Recursion Pharmaceuticals Details AI-Driven Drug Pipeline, Sanofi/Roche Milestones, Runway to 2028

Recursion Pharmaceuticals (NASDAQ:RXRX) Chief Financial Officer Ben Taylor outlined the company's integrated approach to AI-enabled drug discovery and development, recent portfolio decisions...

Sanofi (NASDAQ:SNY) Upgraded to Strong-Buy at Sanford C. Bernstein

Sanford C. Bernstein raised shares of Sanofi to a "strong-buy" rating in a research report on Thursday...

Hudson Bay Capital Management LP Takes Position in Sanofi $SNY

Hudson Bay Capital Management LP acquired a new stake in Sanofi (NASDAQ:SNY - Free Report) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 132,260 shares of the company's stock, valued at approxima...

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

Sanofi - ADR

Peloswing

JFDI

ACInvestorBlog

GPaisa

A pillar of the Stocktwits ecosystem. This award recognizes the member who fosters connection, shares invaluable insights, and elevates the daily discussion to empower their fellow traders, on-platform.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	$1.05	--	--	N/A
Q4 '25	$0.84	$0.91	8.38%	BEAT
Q3 '25	$1.58	$1.69	7.23%	BEAT
Q2 '25	$0.96	$0.91	-5.11%	MISSED
Q1 '25	$0.93	$0.78	-15.53%	MISSED

SNY
Sanofi-Aventis

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest SNY News

SNYSanofi-Aventis